The Psychedelic Executive Order and the New U.S. Push on Psychedelic Research And What It Actually Means for Scientists

Trump’s executive order fast-tracked psychedelic drug research. But signing an order is the easy part. Here’s what research organisations need to know before they order a single milligram.

On April 18, 2026, President Trump signed an executive order aimed at accelerating research on psychedelic substances, specifically naming ibogaine, with psilocybin and MDMA also in scope. To be clear: the order does not reschedule these compounds; they remain Schedule I controlled substances under federal law. What it does is target the administrative bottlenecks that have made research slow and costly, and it does so through three concrete mechanisms.

Psychedelics have spent half a century classified as Schedule I substances under the 1970 Controlled Substances Act, officially regarded as having no accepted medical use and high abuse potential. That classification has not changed. What has changed is the government’s appetite for enabling psychedelics research within that framework, and its willingness to remove some of the procedural friction that has historically made such research so difficult to pursue.

The executive order does three specific things:

1. Directs the FDA to issue Commissioner’s National Priority Vouchers (CNPVs) to psychedelic compounds that have received Breakthrough Therapy designation; a status the FDA grants when preliminary evidence suggests a drug may offer a substantial improvement over existing treatments. These vouchers allow sponsors to jump the review queue, significantly shortening FDA review timelines that would take several months.
2. Instructs the FDA and DEA to establish an expanded use of the Right to Try pathway for investigational psychedelics, allowing seriously ill patients to access substances like ibogaine outside of a formal clinical trial, without waiting for full approval.
3. Commits $50 million through ARPA-H (the health research accelerator) to match investments by state governments in psychedelics research, directly addressing the funding barrier that has kept many academic institutions on the sidelines.

Days after the signing, the FDA cleared the first US-based clinical study of noribogaine, allowing to begin a Phase I trial investigating it as a treatment for alcohol use disorder.

But none of this eliminates the underlying compliance architecture. DEA Schedule I researcher registration is still required before any compound can be acquired or handled. Institutional ethics approvals still follow their own timeline. Record-keeping, secure storage, authorized transport, and staff training obligations are entirely unchanged. For any research organization hoping to work in this space – whether a university, a biotech start-up, or a clinical trial site – understanding that infrastructure is not optional. It’s the foundation everything else is built on.

The order removes some friction from the process. It does not change the process itself. That distinction is where well-intentioned programs run into trouble.

1. The Legislative Landscape: A Patchwork, Not a Map

The first thing to understand about psychedelic regulation is that there is no single global framework. There is a tangle of national laws, international treaties, and regional policies that interact, sometimes harmoniously, sometimes not at all.

At the international level, the 1971 UN Convention on Psychotropic Substances set the baseline. It placed most classical psychedelics (psilocybin, mescaline, LSD, and others) on Schedule I of international control, meaning nations that signed the convention were obliged to restrict their production, distribution, and use. Today, over 180 countries are bound by this treaty. It’s why a research exception that works in Amsterdam still doesn’t automatically translate to Singapore.

The United States

In the US, regulatory authority over controlled substances is split between two agencies. The Drug Enforcement Administration (DEA) controls who can possess, manufacture, or transfer Schedule I compounds. Any researcher who wants to work with these substances needs a Schedule I researcher registration; essentially a federal license specific to their study. Meanwhile, the Food and Drug Administration (FDA) governs clinical trials. Any study involving human participants requires an Investigational New Drug (IND) application, which must include safety data, study protocols, and manufacturing information before a single dose can be given to a volunteer.

The 2026 executive order didn’t eliminate these requirements, but it created tools to move through them faster. CNPVs can compress FDA review from the standard 10-12 months down to a target of 1-2 months. The Right to Try pathway creates a route for seriously ill patients to access investigational substances outside of standard trials. But the DEA registration process, the IND requirement, and the record-keeping obligations all remain intact.

Regulatory approaches vary significantly by region:

• United States: DEA Schedule I registration + FDA IND required. New executive order adds fast-track vouchers and Right to Try pathway for certain patients.
• United Kingdom: Home Office issues Schedule 1 research licenses. Well-established but lengthy process. Strong psilocybin research tradition.
• Netherlands: More permissive environment. National ethics board approval required. Truffles (psilocybin-containing) in a legal grey zone.
• Germany: BfArM oversees approvals. A psilocybin compassionate use program for treatment-resistant depression was approved in 2025; clinical research activity is increasing.
• Australia: Rescheduled MDMA (for PTSD) and psilocybin (for treatment-resistant depression) as medicines in 2023, a global first. Authorized prescribers can now administer them in approved settings.
• Canada: Health Canada issues exemptions for psilocybin-assisted therapy under Section 56 of the Controlled Drugs and Substances Act. Pathway available but not simple.

Important: A compound that is legal to study in one country may be completely prohibited in another, and transit countries matter too. If a substance shipment passes through a jurisdiction with stricter laws, it can be seized even if both origin and destination have valid permits.

2. Is Your Compound Controlled? How to Actually Find Out

This sounds like it should be simple. It rarely is. Drug schedules are not always intuitive, and two layers of law extend control well beyond explicitly named substances. Analogue controls capture compounds that are chemically similar to a scheduled drug and intended for human consumption, catching novel psychoactive substances even if they’ve never appeared in any official list.

Generic controls go further still, sweeping up entire chemical families around known illegal drugs: the US’s generic scheduling of ‘cannabimimetic agents’, for instance, defines controlled substances as compounds that act as CB1 receptor agonists and fall within broadly defined structural classes; a combination that captures an exceptionally large chemical space, meaning a researcher working with a novel cannabinoid-adjacent compound may be handling a controlled substance without realizing it.

Manually cross-referencing national schedules, international lists, and these layered provisions is time-consuming and easy to get wrong. Compliance Checker resolves this in a single step: the software analyses a compound’s chemical structure and automatically screens it against explicit schedules, generic control definitions, and analogue provisions across jurisdictions, delivering a clear controlled-status determination without the need for further manual checks or external consultation.

3. What a Research Organization Is Actually Responsible For

Here’s something that surprises many new entrants to the space: the legal responsibility for compliance doesn’t rest solely with the lead researcher. It sits with the institution. A university, a clinic, or a biotech company that hosts a psychedelic study must have its own registration and controls in place, separate from those of the individual scientist running the project.

The core obligations include:

• Licensing before procurement. No substance can be ordered, received, or handled until all required authorizations are in place. In the US, this means DEA Schedule I researcher registration; in the UK, a Home Office Schedule 1 license.
• Ethics approval. Any human study requires institutional review board (IRB) or ethics committee sign-off before recruitment begins. This is separate from (and in addition to) the regulatory approvals.
• Meticulous record-keeping. Every milligram of a controlled substance must be accounted for. Acquisition, storage, use, and disposal all require documentation. In the US, DEA-registered researchers must conduct annual inventories and report discrepancies promptly.
• A designated responsible person. Most jurisdictions require a named individual, often a Principal Investigator or Controlled Substance Custodian, who is personally accountable for compliance.
• Staff training. Anyone involved in handling-controlled substances must be trained on security protocols, legal requirements, and emergency procedures, and that training must be documented.
• Reporting obligations. Theft, loss, or significant discrepancy must be reported to the DEA (or national equivalent) immediately. Delays in reporting are themselves a compliance violation.

Good practice: Build your compliance infrastructure before you design your study, not after. Applications for DEA registration and institutional authorizations can take months. Starting the process early is the single most effective way to avoid delays.

4. The Logistics Reality: Shipping Is Not Simple

One of the most underestimated challenges in psychedelic research is the sheer complexity of moving substances between locations; even domestically, and even between two fully licensed facilities.

Within the United States

Both the sending and receiving parties must hold valid DEA Schedule I registrations. Transfers require DEA authorization and appropriate controlled substance documentation (such as Form 222 where applicable). Packaging must be tamper-evident, double-sealed, and discreetly labelled, with an unbroken chain of custody record from origin to receipt. The obligation for compliance lies with the registered shipper, and standard consumer courier services are not suitable without the required DEA documentation and secure handling protocols.

Across Borders

International transfers add a substantial layer of complexity. Both origin and destination countries must issue import and export permits through their respective competent authorities, and all movements must comply with International Narcotics Control Board (INCB) requirements under UN treaties. Customs authorities in both countries must be notified in advance, and a freight forwarder with specific experience in controlled substance logistics must be engaged. A general logistics company does not meet these criteria.

Plan ahead: International permit processes routinely take 3 to 6 months, sometimes longer. Factor this into your research timeline from day one. A permit delay can push back your entire study start date, compromise compound stability, and disrupt participant recruitment.

5. The Consequences of Getting It Wrong Under the Psychedelic Executive Order

The consequences of regulatory non-compliance are not administrative inconveniences. Unlicensed handling of Schedule I substances can result in huge penalties, federal criminal charges, revocation of DEA registration, and loss of reputation and federal funding eligibility; any one of which can end a research program permanently. Civil liability follows if a participant is harmed. And in a field that is only now rebuilding public credibility after decades of stigma, a high-profile enforcement action causes damage well beyond the organization involved. Getting the compliance right isn’t just a legal obligation. It’s what protects the science and the scientists working under the Psychedelic Executive Order.

 

This article is for general informational purposes only and does not constitute legal advice. Regulatory requirements vary by jurisdiction and change frequently. Always consult qualified legal and regulatory professionals before commencing research involving controlled substances.